Capricor Therapeutics (LTS:0HTB) Cyclically Adjusted PB Ratio: (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Capricor Therapeutics Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Capricor Therapeutics  (LTS:0HTB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Capricor Therapeutics Cyclically Adjusted PB Ratio Related Terms


Capricor Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics Cyclically Adjusted PB Ratio Chart

Capricor Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.66 0.00 11.76 13.61 26.72

Capricor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.05 10.85 7.78 26.72 24.47

LTS:0HTB vs COAG, DMRA, MPLT: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Capricor Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Capricor Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's Cyclically Adjusted PB Ratio falls into.



Capricor Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Capricor Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Capricor Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=57.812/330.2130*330.2130
=57.812

Current CPI (Mar. 2026) = 330.2130.

Capricor Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 -2.529 241.018 -3.465
201609 0.021 241.428 0.029
201612 -1.773 241.432 -2.425
201703 -3.143 243.801 -4.257
201706 -2.594 244.955 -3.497
201709 -1.427 246.819 -1.909
201712 3.607 246.524 4.831
201803 3.084 249.554 4.081
201806 2.748 251.989 3.601
201809 1.949 252.439 2.549
201812 1.292 251.233 1.698
201903 0.982 254.202 1.276
201906 0.603 256.143 0.777
201909 0.777 256.759 0.999
201912 1.476 256.974 1.897
202003 2.082 258.115 2.664
202006 6.741 257.797 8.635
202009 6.191 260.280 7.854
202012 5.559 260.474 7.047
202103 7.329 264.877 9.137
202106 6.644 271.696 8.075
202109 7.488 274.310 9.014
202112 6.657 278.802 7.885
202203 5.366 287.504 6.163
202206 4.249 296.311 4.735
202209 3.736 296.808 4.156
202212 2.668 296.797 2.968
202303 1.390 301.836 1.521
202306 0.605 305.109 0.655
202309 -0.402 307.789 -0.431
202312 4.970 306.746 5.350
202403 4.067 312.332 4.300
202406 2.562 314.175 2.693
202409 14.750 315.301 15.448
202412 33.313 315.605 34.855
202503 28.315 319.799 29.237
202506 21.826 322.561 22.344
202509 17.135 324.800 17.421
202512 62.625 324.054 63.815
202603 57.812 330.213 57.812

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Capricor Therapeutics Business Description

Other Exchanges CAPR:USA4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.